Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile
item.contributor.advisor
ORCID:
Journal Title
Journal ISSN
Volume Title
Publisher
item.page.isbn
item.page.issn
item.page.issne
item.page.doiurl
item.page.extent
item.page.accessRights
item.page.other
item.page.references
Abstract
Background. The development of effective vaccines against coronavirus disease 2019 is a global priority. CoronaVac is an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccin...
Description
item.page.coverage.spatial
item.page.sponsorship
Citation
ojas Á, Fasce R, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Oyarzún-Arrau A, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Sette A, Zeng G, Meng W, González-Aramundiz JV, Kalergis AM; CoronaVac03CL Study Group. Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile. Clin Infect Dis. 2021 Sep 19:ciab823. doi: 10.1093/cid/ciab823.
Keywords
item.page.dc.rights
item.page.dc.rights.url
Estadísticas de uso
1 0,8 0,5 0,3 0
Septiembre 2025Octubre 2025Noviembre 2025Diciembre 2025Enero 2026Febrero 2026Marzo 2026